Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XXL study: radiotherapy + cetuximab + xevinapant vs radiotherapy + cetuximab in locally advanced SCCHN
2022-502584-38-00Phase 3Completed
- Sponsor
- GORTEC
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Radiotherapy + cetuximab + xevinapant with Radiotherapy + cetuximab + placebo (2 arms). Primary endpoint: Progression-free survival by independent review committee. Started Aug 2023; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2022-502584-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502584-38-00.